A novel bioactive derivative of eicosapentaenoic acid (EPA) suppresses intestinal tumor development in Apc?14/+ mice. (2018)
Attributed to:
A randomised controlled trial of eicosapentaenoic acid (EPA) and/or aspirin for colorectal adenoma (or polyp) preve
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/carcin/bgx136
PubMed Identifier: 29206907
Publication URI: http://europepmc.org/abstract/MED/29206907
Type: Journal Article/Review
Volume: 39
Parent Publication: Carcinogenesis
Issue: 3
ISSN: 0143-3334